Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Synaptogenix, Inc. (SNPX)

6.04   -0.04 (-0.66%) 12-05 16:00
Open: 6.21 Pre. Close: 6.08
High: 6.2484 Low: 5.85
Volume: 38,017 Market Cap: 41(M)

Technical analysis

as of: 2022-12-06 9:22:05 AM
Overall:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 7.84     One year: 8.71
Support: Support1: 5.51    Support2: 4.58
Resistance: Resistance1: 6.71    Resistance2: 7.46
Pivot: 6.18
Moving Average: MA(5): 5.94     MA(20): 6.38
MA(100): 6.97     MA(250): 6.86
MACD: MACD(12,26): -0.3     Signal(9): -0.2
Stochastic oscillator: %K(14,3): 31     %D(3): 26.2
RSI: RSI(14): 43.4
52-week: High: 10.64  Low: 3.78
Average Vol(K): 3-Month: 57 (K)  10-Days: 58 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ SNPX ] has closed above bottom band by 37.1%. Bollinger Bands are 28.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 6.26 - 6.29 6.29 - 6.32
Low: 5.77 - 5.81 5.81 - 5.84
Close: 5.98 - 6.04 6.04 - 6.1

Company Description

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.

Headline News

Fri, 18 Nov 2022
NeoGenomics, Inc. (NEO) Stock Falls -9.51% This Week: Is It a Good Pick? - InvestorsObserver

Fri, 18 Nov 2022
Is Synaptogenix Inc (SNPX) a Smart Choice in Biotechnology Friday? - InvestorsObserver

Thu, 03 Nov 2022
Should Biotechnology Stock Synaptogenix Inc (SNPX) Be in Your Portfolio Thursday? - InvestorsObserver

Wed, 19 Oct 2022
Synaptogenix to Present at ThinkEquity Investor Conference on October 26, 2022 - PR Newswire

Tue, 11 Oct 2022
Chen Reveals His Picks for Last Quarter - Streetwise Reports

Wed, 28 Sep 2022
Synaptogenix Welcomes Lecanemab Phase 3 Trial Results - PR Newswire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Outperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 7 (M)
Shares Float 6 (M)
% Held by Insiders 17.4 (%)
% Held by Institutions 7 (%)
Shares Short 223 (K)
Shares Short P.Month 278 (K)

Stock Financials

EPS -2.12
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 3.9
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -30.4
Return on Equity (ttm) -49.3
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -2.12
Qtrly Earnings Growth 0
Operating Cash Flow -10 (M)
Levered Free Cash Flow -5 (M)

Stock Valuations

PE Ratio -2.85
PEG Ratio 0
Price to Book value 1.54
Price to Sales 0
Price to Cash Flow -3.96

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.